封面
市場調查報告書
商品編碼
1526081

細胞表面標誌物的全球市場

Cell Surface Markers

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 683 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年,全球細胞表面標誌物市場預計將達到 15 億美元

細胞表面標誌物的全球市場預計 2023 年為 8.056 億美元,預計到 2030 年將達到 15 億美元,在 2023-2030 年分析期間複合年成長率為 9.2%。抗體是本報告分析的細分市場之一,預計複合年成長率為 10.9%,到分析期結束時將達到 9.811 億美元。在分析期間,PCR 陣列領域的複合年成長率估計為 6.5%。

美國市場預估為3.695億美元,中國預期複合年成長率為11.1%

預計 2023 年美國細胞表面標誌物市場規模將達到 3.695 億美元。中國作為世界第二大經濟體,預計到 2030 年市場規模將達到 1.311 億美元,2023-2030 年分析期間複合年成長率為 11.1%。其他值得注意的區域市場包括日本和加拿大,在分析期間預計複合年成長率分別為 7.8% 和 8.5%。在歐洲,德國的複合年成長率預計約為 8.2%。

全球細胞表面標誌物市場 - 主要趨勢和促進因素概述

細胞表面標誌物,也稱為細胞表面抗原,是位於細胞膜上的特異性蛋白質或分子,作為獨特的標識符,在細胞通訊和免疫反應中發揮重要作用。這些標記對於細胞訊號傳導、黏附和遷移等各種生物過程至關重要。特別是在免疫細胞中,研究人員和臨床醫生經常使用它來識別和分類不同的細胞類型。例如,CD4 和 CD8 標記分別用於區分輔助 T 細胞和細胞毒性 T 細胞。這些標記物的識別對於理解癌症、自體免疫疾病和感染疾病等各種疾病的細胞機制至關重要,並且它們經常成為診斷和治療應用的目標。

隨著流式細胞技術、質量細胞儀和免疫組織化學等先進技術的發展,細胞表面標誌物的特性取得了顯著進展。特別是,流式細胞技術可以同時快速且準確地分析異質群體中單一細胞的多個標記。此技術可用於免疫表現型分析,可詳細研究免疫細胞亞群及其在健康和疾病中的功能。質譜細胞儀或飛行時間細胞儀 (CyTOF) 是傳統流式細胞技術的延伸,它使用金屬標記的抗體來增加可檢測標記的數量,並提供對細胞複雜性的深入了解。免疫組織化學使用細胞表面標誌物物特異性抗體對組織切片進行染色,使研究人員能夠觀察組織內標記物的定位和分佈,並提供空間背景。這些進步大大提高了我們診斷疾病、監測治療反應和開發標標靶治療的能力。

細胞表面標誌物市場的發展受到多種因素的推動,例如慢性病盛行率上升、技術進步以及研發活動的活性化。癌症、自體免疫疾病和感染疾病的日益普及增加了對能夠準確識別和表徵細胞群的診斷工具的需求。高通量篩檢方法和分析技術的技術進步使得更高精度、更大規模地分析細胞表面標誌物成為可能。此外,個人化醫療和免疫療法的激增需要開發用於標靶治療策略的新型標記物。製藥和生物技術公司正在大力投資發現和檢驗新標記物,以提高治療的功效和特異性。旨在促進生物醫學研究的政府資助和舉措進一步推動了市場成長。總的來說,這些因素凸顯了市場動態的動態性和擴展性,並強調了它們在推進醫學研究和改善患者照護的關鍵作用。

受訪企業範例(70家知名企業)

  • Abbott Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • BD Biosciences
  • Bio-Techne Corporation
  • Cosmo Bio Co., Ltd.
  • A. Menarini Diagnostics Srl
  • BML, Inc.
  • Cellavision AB
  • Diatron MI Zrt
  • Apogee Flow Systems Ltd.
  • Cytonome/ST, LLC
  • Dako Denmark A/S
  • ACEA Biosciences, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 阿爾迪
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP-7908

Global Cell Surface Markers Market to Reach US$1.5 Billion by 2030

The global market for Cell Surface Markers estimated at US$805.6 Million in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. Antibodies, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$981.1 Million by the end of the analysis period. Growth in the PCR Arrays segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$369.5 Million While China is Forecast to Grow at 11.1% CAGR

The Cell Surface Markers market in the U.S. is estimated at US$369.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$131.1 Million by the year 2030 trailing a CAGR of 11.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Cell Surface Markers Market - Key Trends & Drivers Summarized

Cell surface markers, also known as cell surface antigens, are specific proteins or molecules present on the membrane of cells that serve as unique identifiers and play crucial roles in cellular communication and immune response. These markers are integral to various biological processes, including cell signaling, adhesion, and migration. They are often used by researchers and clinicians to identify and classify different cell types, especially in the context of immune cells. For instance, CD4 and CD8 markers are used to distinguish between helper T cells and cytotoxic T cells, respectively. The identification of these markers is pivotal in understanding the cellular mechanisms underlying various diseases, including cancer, autoimmune disorders, and infectious diseases, and they are frequently targeted in diagnostic and therapeutic applications.

The characterization of cell surface markers has advanced significantly with the development of sophisticated technologies such as flow cytometry, mass cytometry, and immunohistochemistry. Flow cytometry, in particular, allows for the rapid and precise analysis of multiple markers simultaneously on individual cells within heterogeneous populations. This technology has been instrumental in immunophenotyping, enabling the detailed study of immune cell subsets and their functions in health and disease. Mass cytometry, or cytometry by time-of-flight (CyTOF), expands on traditional flow cytometry by using metal-tagged antibodies, increasing the number of detectable markers and providing deeper insights into cellular complexity. Immunohistochemistry, which involves the staining of tissue sections with antibodies specific to cell surface markers, provides spatial context, allowing researchers to observe the localization and distribution of markers within tissues. These advancements have significantly enhanced our ability to diagnose diseases, monitor treatment responses, and develop targeted therapies.

The growth in the cell surface markers market is driven by several factors, including the rising prevalence of chronic diseases, advancements in technology, and increasing research and development activities. The growing incidence of cancers, autoimmune diseases, and infectious diseases has led to heightened demand for diagnostic tools that can accurately identify and characterize cell populations. Technological advancements in high-throughput screening methods and analytical techniques have made it possible to analyze cell surface markers with greater precision and at a larger scale. Additionally, the surge in personalized medicine and immunotherapy has necessitated the development of novel markers for targeted treatment strategies. Pharmaceutical and biotechnology companies are investing heavily in the discovery and validation of new markers to enhance the efficacy and specificity of therapeutics. Government funding and initiatives aimed at advancing biomedical research further support market growth. These factors collectively highlight the dynamic and expanding nature of the cell surface markers market, underscoring its critical role in advancing medical research and improving patient care.

Select Competitors (Total 70 Featured) -

  • Abbott Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • BD Biosciences
  • Bio-Techne Corporation
  • Cosmo Bio Co., Ltd.
  • A. Menarini Diagnostics Srl
  • BML, Inc.
  • Cellavision AB
  • Diatron MI Zrt
  • Apogee Flow Systems Ltd.
  • Cytonome/ST, LLC
  • Dako Denmark A/S
  • ACEA Biosciences, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Cell Surface Markers: A Prelude
    • Cell Surface Markers - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Robust Demand for Analytical Techniques and Focus on Timely Diagnosis Drive Growth of Global Cell Surface Markers Market
    • Research Dominates Cell Surface Markers Market, Clinical Diagnostics to Exhibit Fastest Growth
    • Flow Cytometers Lead the Cell Surface Markers Market
    • T and B Cells Dominate the Market
    • Developed Regions: Major Revenue Contributors
    • Developing Regions Drive Future Growth
    • Recent Market Activity
    • Innovations & Advancements
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Uptake in Drug Discovery Applications Widens Market Prospects
    • Role of Flow Cytometry in Cell Line Development
    • Multicolor Flow Cytometry Offers Perfect Option to Understand B-Cell Development
    • Hematology Analyzers Gain Traction in Cell Surface Marker Identification
    • Growing Hematology Analyzers Market Witnesses Steady Growth
    • Key Technology Trends in Hematology Analyzers Market
    • Rising Cancer Incidence Worldwide Spurs Demand For Cell Surface Markers
    • Select Markers for Cancer Stem Cell Identification
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Use of CD Markers in Identification and Classification of Leukocyte Populations
    • Most Common CD markers for Flow Cytometry
    • Growing Significance of Personalized Medicine: An Opportunity for Cell Surface Markers
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019 and 2024
    • RNA Sequencing Emerges as Potential Approach to Identify Cell Surface Markers for Enabling Precision Medicine
    • Cell Surface Markers Grows Significantly in Stem Cell Research
    • Select Cell Surface Markers Used in Stem Cell Identification and Characterization
    • Hematopoietic Stem Cell Markers Provide Useful Insights into Hematopoiesis
    • Genetically Engineered CAR T-Cells Present Potential Weapon to Eliminate Cancer Stem Cells and Prevent Recurrence of Cancer
    • Key Models
    • CSC Population & Noteworthy Markers
  • ALDH
    • CD44
    • CD90
    • CD133
    • EpCAM & EGFR
    • Immunotherapy Targets Natural Killer Cells to Offer Hope for Cancer Patients
    • Cell Surface Markers Identification Assumes Critical Importance amid Growing Prevalence of Chronic Diseases
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Aging Demographics Present Opportunities for Cell Surface Markers
    • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
    • Clinical Management of Autoimmune Diseases
    • Flow Cytometry Remains the Gold Standard in HIV Testing and Monitoring
    • Increased Emphasis on Lab Automation Builds Opportunities
    • Increasing Investments on Advanced Equipment in Disease Diagnosis Underpin Volume Growth
    • Growing Focus on Data Management in Research Programs Extends Opportunities
    • Rat Markers
    • Lineage and Antibodies Specific Rat Markers
    • Commonly Used Key Rat Markers by Antibodies and Research Area/Target Cell
    • New Anti-Rat Antibodies Products Expand Scope of Applications
    • ED Clone Anti-Rat Antibodies by Marker and Cell Type
    • Rat Flow Cytometry Panels
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Cell Surface Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Cell Surface Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for PCR Arrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for PCR Arrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for PCR Arrays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for T Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for T Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for T Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for B Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for B Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for B Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for NK Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for NK Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for NK Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Monocyte Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Monocyte Cell by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Monocyte Cell by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Cell Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Clinical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Hospitals & Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Hospitals & Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 36: World 16-Year Perspective for Hospitals & Clinical Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 39: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 40: World Cell Surface Markers Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • Largest Market for Cell Surface Markers
    • Rising Cancer Cases Spur Growth in Cell Surface Markers Market
    • Market Benefits from Growing Funding for Stem Cell Research
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • High Focus on Improving Healthcare Augurs Well for Market Growth
  • JAPAN
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 77: China Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: China 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: China 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: China 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: China 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • Increasing Cancer Research to Drive Cell Surface Markers Market
  • EUROPE
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Cell Surface Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
  • FRANCE
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: France 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: France 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: France 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: France 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Germany 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Italy 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Italy 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Italy 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Italy 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 140: UK Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: UK 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: UK 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: UK 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: UK 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Spain 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Spain 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Spain 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Spain 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Russia 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Russia 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Russia 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Russia 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Rest of Europe 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Rest of Europe 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Rest of Europe 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Europe 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Cell Surface Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Asia-Pacific 16-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Asia-Pacific 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Asia-Pacific 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Asia-Pacific 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • Increased Cancer Research to Drive the Market for Cell Surface Markers
  • AUSTRALIA
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Australia 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Australia 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Australia 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Australia 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 215: India Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: India 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: India 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: India 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: India 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • India Eyes on RT-LAMP Kits to Ramp up COVID-19 Testing Capacity
    • Molecular Diagnostic Market in India to Witness Significant Growth
    • Growth Drivers in a Nut Shell
  • SOUTH KOREA
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: South Korea 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: South Korea 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: South Korea 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: South Korea 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Cell Surface Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Latin America 16-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Latin America 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Latin America 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Latin America 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Argentina 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Argentina 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Argentina 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Argentina 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Brazil 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: Brazil 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: Brazil 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: Brazil 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: Mexico 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Mexico 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Mexico 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Mexico 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Rest of Latin America 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: Rest of Latin America 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 310: Rest of Latin America 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 313: Rest of Latin America 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Cell Surface Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 316: Middle East 16-Year Perspective for Cell Surface Markers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 319: Middle East 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 322: Middle East 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 325: Middle East 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 328: Middle East 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 331: Iran 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 334: Iran 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 337: Iran 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 340: Iran 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 343: Israel 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 346: Israel 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 349: Israel 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 352: Israel 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 355: Saudi Arabia 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 358: Saudi Arabia 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 361: Saudi Arabia 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 364: Saudi Arabia 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 367: UAE 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 370: UAE 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 373: UAE 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 376: UAE 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 379: Rest of Middle East 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 382: Rest of Middle East 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 385: Rest of Middle East 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 388: Rest of Middle East 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Cell Surface Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Cell Surface Markers by Product - Antibodies and PCR Arrays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Cell Surface Markers by Product - Antibodies and PCR Arrays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 391: Africa 16-Year Perspective for Cell Surface Markers by Product - Percentage Breakdown of Value Sales for Antibodies and PCR Arrays for the Years 2014, 2024 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Cell Surface Markers by Cell Type - T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 394: Africa 16-Year Perspective for Cell Surface Markers by Cell Type - Percentage Breakdown of Value Sales for T Cell, B Cell, NK Cell, Monocyte Cell and Other Cell Types for the Years 2014, 2024 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Cell Surface Markers by Application - Research and Clinical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Cell Surface Markers by Application - Research and Clinical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 397: Africa 16-Year Perspective for Cell Surface Markers by Application - Percentage Breakdown of Value Sales for Research and Clinical for the Years 2014, 2024 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Cell Surface Markers by End-Use - Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 400: Africa 16-Year Perspective for Cell Surface Markers by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Hospitals & Clinical Laboratories and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION